Cure My Disease

Don't miss your cure!

 Log in / Sign up

New cell therapy aims to make mismatched donor transplants safer for blood cancer patients

NCT ID NCT06551584

Recruiting now Disease control Sponsor: Stanford University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests a cell therapy called Orca-T combined with standard drugs to prevent graft-versus-host disease (GVHD) in 24 adults with advanced blood cancers (like leukemia or MDS) receiving stem cell transplants from partially matched donors. The main goal is to see if this approach reduces severe transplant complications, such as graft failure or serious infections, within the first 100 days. Participants must be in remission or have low blast counts and be between 18 and 70 years old.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute biphenotypic leukemia acute lymphoblastic leukemia acute myeloid leukemia mixed phenotype acute leukemia myelodysplastic syndrome Myelodysplastic Syndromes Precursor Cell Lymphoblastic Leukemia-Lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE LYMPHOID LEUKEMIA ACUTE MYELOID LEUKEMIA MIXED PHENOTYPE ACUTE LEUKEMIA MYELODYSPLASTIC SYNDROMES

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Stanford University

    RECRUITING

    Palo Alto, California, 94304, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.